- PharmAust (PAA) doses the first patient in the second cohort of its motor neurone disease (MND) trial for its monepantel (MPL) product
- The company’s testing showed MPL was “well-tolerated” by all MND patients at the first dosing level, leading the company to supply tablets to all six patients in cohort one that elected to remain on the treatment
- PharmAust says it will now focus on enrolling a further five patients to complete the cohort two group of six patients in its phase one/two clinical trial, which will be a “key determinant” in proceeding to a phase two trial in MND
- The company’s trials are being assisted by a funding commitment from FightMND of around $800,000 for a phase one/two trial examining the effects of MPL in MND
- PharmAust shares are trading at 8.1 cents at 1:54 pm AEDT
PharmAust (PAA) has dosed the first patient in the second cohort of its motor neurone disease (MND) trial for its monepantel (MPL) product.
The trial is testing the effects of MPL in individuals living with MND.
The company’s testing showed MPL was “well-tolerated” by all MND patients at the first dosing level, leading it to supply tablets to all six patients in cohort one that elected to remain on the treatment.
PharmAust said MPL was shown to potentially reduce the rate of degeneration and loss of motor neurons in the anterior horns and motor nuclei of the brainstem.
The first patient dosed has now surpassed 140 days of treatment and displayed no material safety issues or serious adverse events. PAA said patients from the first cohort would continue to be monitored for cognitive function.
PharmAust said it would now focus on enrolling a further five patients to complete the cohort two group of six patients in its phase one/two clinical trial, which would be a “key determinant” in proceeding to a phase two trial in MND.
Continued safety and efficacy data from the trial will also be used to facilitate a phase two study in COVID-19 patients.
MND affects over 350,000 people globally and kills more than 100,000 people every year. The disease is invariably fatal, with the average life expectancy of someone with MND being around 27 months.
PharmAust’s trials are being assisted by a funding commitment from FightMND of $881,085 for a phase one/two trial examining the effects of MPL in MND, otherwise known as Lou Gehrig’s disease or Amyotrophic Lateral Sclerosis (ALS).
PharmAust shares were trading at 8.1 cents at 1:54 pm AEDT.